Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Neuroinflammation markers and methyl alcohol induced toxic brain damage.

Zakharov S, Hlusicka J, Nurieva O, Kotikova K, Lischkova L, Kacer P, Kacerova T, Urban P, Vaneckova M, Seidl Z, Diblik P, Kuthan P, Heissigerova J, Lesovsky J, Rulisek J, Vojtova L, Hubacek JA, Navratil T.

Toxicol Lett. 2018 May 4. pii: S0378-4274(18)30175-9. doi: 10.1016/j.toxlet.2018.05.001. [Epub ahead of print]

PMID:
29733875
2.

Progressive Chronic Retinal Axonal Loss Following Acute Methanol-induced Optic Neuropathy: Four-Year Prospective Cohort Study.

Nurieva O, Diblik P, Kuthan P, Sklenka P, Meliska M, Bydzovsky J, Heissigerova J, Urban P, Kotikova K, Navratil T, Komarc M, Seidl Z, Vaneckova M, Pelclova D, Zakharov S.

Am J Ophthalmol. 2018 Jul;191:100-115. doi: 10.1016/j.ajo.2018.04.015. Epub 2018 Apr 28.

3.

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients.

Kadrnozkova L, Vaneckova M, Sobisek L, Benova B, Kucerova K, Motyl J, Andelova M, Novotna K, Lizrova Preiningerova J, Krasensky J, Havrdova E, Horakova D, Uher T.

J Neurol Sci. 2018 May 15;388:87-93. doi: 10.1016/j.jns.2018.02.045. Epub 2018 Mar 6.

PMID:
29627038
4.

Role of activation of lipid peroxidation in the mechanisms of acute methanol poisoning.

Hlusicka J, Loster T, Lischkova L, Vaneckova M, Seidl Z, Diblik P, Kuthan P, Urban P, Navratil T, Kacer P, Zakharov S.

Clin Toxicol (Phila). 2018 Apr 2:1-11. doi: 10.1080/15563650.2018.1455980. [Epub ahead of print]

PMID:
29607701
5.

Establishing pathological cut-offs for lateral ventricular volume expansion rates.

Dwyer MG, Hagemeier J, Bergsland N, Horakova D, Korn JR, Khan N, Uher T, Medin J, Silva D, Vaneckova M, Havrdova EK, Zivadinov R.

Neuroimage Clin. 2018 Feb 7;18:494-501. doi: 10.1016/j.nicl.2018.02.009. eCollection 2018.

6.

The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis.

Uher T, Krasensky J, Sobisek L, Seidl Z, Bergsland N, Dwyer MG, Kubala Havrdova E, Zivadinov R, Horakova D, Vaneckova M.

J Neuroimaging. 2018 May;28(3):328-337. doi: 10.1111/jon.12505. Epub 2018 Feb 27.

PMID:
29485230
7.

Cognitive clinico-radiological paradox in early stages of multiple sclerosis.

Uher T, Krasensky J, Sobisek L, Blahova Dusankova J, Seidl Z, Kubala Havrdova E, Sormani MP, Horakova D, Kalincik T, Vaneckova M.

Ann Clin Transl Neurol. 2017 Dec 15;5(1):81-91. doi: 10.1002/acn3.512. eCollection 2018 Jan.

8.

Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study.

Bergsland N, Horakova D, Dwyer MG, Uher T, Vaneckova M, Tyblova M, Seidl Z, Krasensky J, Havrdova E, Zivadinov R.

Neuroimage Clin. 2017 Nov 5;17:444-451. doi: 10.1016/j.nicl.2017.11.002. eCollection 2018.

9.

Characteristics of motor speech phenotypes in multiple sclerosis.

Rusz J, Benova B, Ruzickova H, Novotny M, Tykalova T, Hlavnicka J, Uher T, Vaneckova M, Andelova M, Novotna K, Kadrnozkova L, Horakova D.

Mult Scler Relat Disord. 2018 Jan;19:62-69. doi: 10.1016/j.msard.2017.11.007. Epub 2017 Nov 8.

PMID:
29149697
10.

Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.

Uher T, Vaneckova M, Krasensky J, Sobisek L, Tyblova M, Volna J, Seidl Z, Bergsland N, Dwyer MG, Zivadinov R, De Stefano N, Sormani MP, Havrdova EK, Horakova D.

Mult Scler. 2017 Nov 1:1352458517742739. doi: 10.1177/1352458517742739. [Epub ahead of print]

PMID:
29143562
11.

[Treatment of pituitary adenomas].

Ježková J, Marek J, Vaněčková M.

Cas Lek Cesk. 2017 Fall;156(5):266-270. Czech.

PMID:
28992711
12.

Gait and Balance Impairment after Acute Methanol Poisoning.

Peterová K, Brožová H, Klempíř J, Lišková I, Bezdicek O, Ridzoň P, Vaněčková M, Zakharov S, Pelclová D, Miovský M, Růžička E.

Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):176-182. doi: 10.1111/bcpt.12853. Epub 2017 Sep 6.

PMID:
28724204
13.

Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis.

Dwyer MG, Silva D, Bergsland N, Horakova D, Ramasamy D, Durfee J, Vaneckova M, Havrdova E, Zivadinov R.

Neuroimage Clin. 2017 Jun 19;15:769-779. doi: 10.1016/j.nicl.2017.06.022. eCollection 2017.

14.

A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study.

Uher T, Krasensky J, Vaneckova M, Sobisek L, Seidl Z, Havrdova E, Bergsland N, Dwyer MG, Horakova D, Zivadinov R.

J Neuroimaging. 2017 Nov;27(6):620-629. doi: 10.1111/jon.12445. Epub 2017 May 2.

PMID:
28464417
15.

Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.

Burgetova A, Dusek P, Vaneckova M, Horakova D, Langkammer C, Krasensky J, Sobisek L, Matras P, Masek M, Seidl Z.

AJNR Am J Neuroradiol. 2017 Jun;38(6):1079-1086. doi: 10.3174/ajnr.A5166. Epub 2017 Apr 27.

16.

Cognitive sequelae of methanol poisoning involve executive dysfunction and memory impairment in cross-sectional and long-term perspective.

Bezdicek O, Michalec J, Vaneckova M, Klempir J, Liskova I, Seidl Z, Janikova B, Miovsky M, Hubacek J, Diblik P, Kuthan P, Pilin A, Kurcova I, Fenclova Z, Petrik V, Navratil T, Pelclova D, Zakharov S, Ruzicka E.

Alcohol. 2017 Mar;59:27-35. doi: 10.1016/j.alcohol.2016.12.003. Epub 2016 Dec 10.

PMID:
28262185
17.

Leukotriene-mediated neuroinflammation, toxic brain damage, and neurodegeneration in acute methanol poisoning.

Zakharov S, Kotikova K, Nurieva O, Hlusicka J, Kacer P, Urban P, Vaneckova M, Seidl Z, Diblik P, Kuthan P, Navratil T, Pelclova D.

Clin Toxicol (Phila). 2017 Apr;55(4):249-259. doi: 10.1080/15563650.2017.1284332. Epub 2017 Feb 6.

PMID:
28165820
18.

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.

Uher T, Fellows K, Horakova D, Zivadinov R, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, Bergsland N, Weinstock-Guttman B, Havrdova E, Ramanathan M.

J Lipid Res. 2017 Feb;58(2):403-411. doi: 10.1194/jlr.M072751. Epub 2016 Dec 6.

19.

Is Chelation Therapy Efficient for the Treatment of Intravenous Metallic Mercury Intoxication?

Pelclova D, Vlckova S, Bezdicek O, Vaneckova M, Urban P, Ridzon P, Diblik P, Navratil T, Klusackova P, Vlcek K, Benesova O, Trestik P, Homolka J, Zakharov S.

Basic Clin Pharmacol Toxicol. 2017 Jun;120(6):628-633. doi: 10.1111/bcpt.12725. Epub 2017 Jan 17.

20.

Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach.

Uher T, Vaneckova M, Sormani MP, Krasensky J, Sobisek L, Dusankova JB, Seidl Z, Havrdova E, Kalincik T, Benedict RH, Horakova D.

Eur J Neurol. 2017 Feb;24(2):292-301. doi: 10.1111/ene.13200. Epub 2016 Nov 22.

PMID:
27873386
21.

Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study.

Zivadinov R, Ramasamy DP, Vaneckova M, Gandhi S, Chandra A, Hagemeier J, Bergsland N, Polak P, Benedict RH, Hojnacki D, Weinstock-Guttman B.

Mult Scler. 2017 Sep;23(10):1336-1345. doi: 10.1177/1352458516678083. Epub 2016 Nov 4.

PMID:
27811339
22.

Reliable measurements of brain atrophy in individual patients with multiple sclerosis.

Smeets D, Ribbens A, Sima DM, Cambron M, Horakova D, Jain S, Maertens A, Van Vlierberghe E, Terzopoulos V, Van Binst AM, Vaneckova M, Krasensky J, Uher T, Seidl Z, De Keyser J, Nagels G, De Mey J, Havrdova E, Van Hecke W.

Brain Behav. 2016 Jul 19;6(9):e00518. eCollection 2016 Sep.

23.

Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?

Uher T, Havrdova E, Sobisek L, Krasensky J, Vaneckova M, Seidl Z, Tyblova M, Ramasamy D, Zivadinov R, Horakova D.

Mult Scler. 2017 Feb;23(2):242-252. doi: 10.1177/1352458516650525. Epub 2016 Jul 11.

PMID:
27230790
24.

Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.

Zivadinov R, Jakimovski D, Gandhi S, Ahmed R, Dwyer MG, Horakova D, Weinstock-Guttman B, Benedict RR, Vaneckova M, Barnett M, Bergsland N.

Expert Rev Neurother. 2016 Jul;16(7):777-93. doi: 10.1080/14737175.2016.1181543. Epub 2016 May 13. Review.

PMID:
27105209
25.

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.

Uher T, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, Ramasamy D, Zivadinov R, Havrdova E, Kalincik T, Horakova D.

Mult Scler. 2017 Jan;23(1):51-61. doi: 10.1177/1352458516642314. Epub 2016 Jul 11.

PMID:
27053635
26.

Imaging findings after methanol intoxication (cohort of 46 patients).

Vaneckova M, Zakharov S, Klempir J, Ruzicka E, Bezdicek O, Brozova H, Diblik P, Miovsky M, Hubacek JA, Urban P, Ridzon P, Pelclova D, Burgetova A, Masek M, Kotikova K, Peterova K, Liskova I, Hamplova L, Seidl Z.

Neuro Endocrinol Lett. 2015;36(8):737-44.

PMID:
26921573
27.

A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.

Zivadinov R, Uher T, Hagemeier J, Vaneckova M, Ramasamy DP, Tyblova M, Bergsland N, Seidl Z, Dwyer MG, Krasensky J, Havrdova E, Horakova D.

Mult Scler. 2016 Nov;22(13):1709-1718. Epub 2016 Feb 16.

PMID:
26883943
28.

Hippocampal but not amygdalar volume loss in narcolepsy with cataplexy.

Nemcova V, Krasensky J, Kemlink D, Petrovicky P, Vaneckova M, Seidl Z, Rulseh A, Buskova J, Susta M, Sonka K.

Neuro Endocrinol Lett. 2015 Dec;36(7):682-8.

PMID:
26859591
29.

Acute Methanol Poisoning: Prevalence and Predisposing Factors of Haemorrhagic and Non-Haemorrhagic Brain Lesions.

Zakharov S, Kotikova K, Vaneckova M, Seidl Z, Nurieva O, Navratil T, Caganova B, Pelclova D.

Basic Clin Pharmacol Toxicol. 2016 Aug;119(2):228-38. doi: 10.1111/bcpt.12559. Epub 2016 Feb 10.

30.

LOW-BACK PAIN DISORDERS AS OCCUPATIONAL DISEASES IN THE CZECH REPUBLIC AND 22 EUROPEAN COUNTRIES: COMPARISON OF NATIONAL SYSTEMS, RELATED DIAGNOSES AND EVALUATION CRITERIA.

Laštovková A, Nakládalová M, Fenclová Z, Urban P, Gad'ourek P, Lebeda T, Ehler E, Ridzoň P, Hlávková J, Boriková A, Kuijer PP, Bátora I, Scholz-Odermatt SM, Moldovan H, Godderis L, Leijon O, Campo G, Vaněčková M, Bonneterre V, Stikova EJ, Pelclová D.

Cent Eur J Public Health. 2015 Sep;23(3):244-51.

31.

Long-term visual damage after acute methanol poisonings: Longitudinal cross-sectional study in 50 patients.

Zakharov S, Pelclova D, Diblik P, Urban P, Kuthan P, Nurieva O, Kotikova K, Navratil T, Komarc M, Belacek J, Seidl Z, Vaneckova M, Hubacek JA, Bezdicek O, Klempir J, Yurchenko M, Ruzicka E, Miovsky M, Janikova B, Hovda KE.

Clin Toxicol (Phila). 2015 Nov;53(9):884-92. doi: 10.3109/15563650.2015.1086488. Epub 2015 Sep 12.

PMID:
26364866
32.

Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.

Uher T, Horakova D, Tyblova M, Zeman D, Krasulova E, Mrazova K, Seidl Z, Vaneckova M, Krasensky J, Weinstock-Guttman B, Ramanathan M, Havrdova E, Zivadinov R.

Mult Scler. 2016 May;22(6):770-81. doi: 10.1177/1352458515601903. Epub 2015 Sep 11.

PMID:
26362893
33.

Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.

Fellows K, Uher T, Browne RW, Weinstock-Guttman B, Horakova D, Posova H, Vaneckova M, Seidl Z, Krasensky J, Tyblova M, Havrdova E, Zivadinov R, Ramanathan M.

J Lipid Res. 2015 Oct;56(10):2010-8. doi: 10.1194/jlr.M060970. Epub 2015 Aug 4.

34.

The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study).

Vaneckova M, Herman M, Smith MP, Mechl M, Maravilla KR, Weichet J, Spampinato MV, Žižka J, Wippold FJ 2nd, Baima JJ, Babbel R, Bültmann E, Huang RY, Buhk JH, Bonafé A, Colosimo C, Lui S, Kirchin MA, Shen N, Pirovano G, Spinazzi A.

AJNR Am J Neuroradiol. 2015 Sep;36(9):1589-98. doi: 10.3174/ajnr.A4468. Epub 2015 Jul 16.

35.

Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome.

Varosanec M, Uher T, Horakova D, Hagemeier J, Bergsland N, Tyblova M, Seidl Z, Vaneckova M, Krasensky J, Dwyer MG, Havrdova E, Zivadinov R.

AJNR Am J Neuroradiol. 2015 Aug;36(8):1457-64. doi: 10.3174/ajnr.A4330. Epub 2015 Jun 25.

36.

Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.

Uher T, Horakova D, Kalincik T, Bergsland N, Tyblova M, Ramasamy DP, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.

Eur J Neurol. 2015 Jul;22(7):1113-23. doi: 10.1111/ene.12716. Epub 2015 Apr 22.

PMID:
25904020
37.

Successful Use of Hydroxocobalamin and Sodium Thiosulfate in Acute Cyanide Poisoning: A Case Report with Follow-up.

Zakharov S, Vaneckova M, Seidl Z, Diblik P, Kuthan P, Urban P, Navratil T, Pelclova D.

Basic Clin Pharmacol Toxicol. 2015 Sep;117(3):209-12. doi: 10.1111/bcpt.12387. Epub 2015 Feb 25.

38.

Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment.

Uher T, Benedict RH, Horakova D, Bergsland N, Dusankova JB, Tyblova M, Ramasamy DP, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.

J Neurol Sci. 2014 Dec 15;347(1-2):229-34. doi: 10.1016/j.jns.2014.10.002. Epub 2014 Oct 8.

PMID:
25456460
39.

MRI correlates of disability progression in patients with CIS over 48 months.

Uher T, Horakova D, Bergsland N, Tyblova M, Ramasamy DP, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.

Neuroimage Clin. 2014 Sep 28;6:312-9. doi: 10.1016/j.nicl.2014.09.015. eCollection 2014.

40.

Czech mass methanol outbreak 2012: epidemiology, challenges and clinical features.

Zakharov S, Pelclova D, Urban P, Navratil T, Diblik P, Kuthan P, Hubacek JA, Miovsky M, Klempir J, Vaneckova M, Seidl Z, Pilin A, Fenclova Z, Petrik V, Kotikova K, Nurieva O, Ridzon P, Rulisek J, Komarc M, Hovda KE.

Clin Toxicol (Phila). 2014 Dec;52(10):1013-24. doi: 10.3109/15563650.2014.974106. Epub 2014 Oct 25.

PMID:
25345388
41.

Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study).

Maravilla KR, Smith MP, Vymazal J, Goyal M, Herman M, Baima JJ, Babbel R, Vaneckova M, Žižka J, Colosimo C, Urbańczyk-Zawadzka M, Mechl M, Bag AK, Bastianello S, Bueltmann E, Hirai T, Frattini T, Kirchin MA, Pirovano G.

AJNR Am J Neuroradiol. 2015 Jan;36(1):14-23. doi: 10.3174/ajnr.A4154. Epub 2014 Oct 9.

42.

Rare alleles within the CYP2E1 (MEOS system) could be associated with better short-term health outcome after acute methanol poisoning.

Hubacek JA, Pelclova D, Seidl Z, Vaneckova M, Klempir J, Ruzicka E, Ridzon P, Urban P, Fenclova Z, Petrik V, Diblik P, Kuthan P, Miovsky M, Janikova B, Adamkova V, Zakharov S.

Basic Clin Pharmacol Toxicol. 2015 Feb;116(2):168-72. doi: 10.1111/bcpt.12310. Epub 2014 Sep 19.

43.

Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome.

Uher T, Blahova-Dusankova J, Horakova D, Bergsland N, Tyblova M, Benedict RH, Kalincik T, Ramasamy DP, Seidl Z, Hagermeier J, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.

J Neurol. 2014 Sep;261(9):1735-44. doi: 10.1007/s00415-014-7413-9. Epub 2014 Jun 22.

PMID:
24952618
44.

Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study.

Browne RW, Weinstock-Guttman B, Zivadinov R, Horakova D, Bodziak ML, Tamaño-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Qu J, Havrdova E, Ramanathan M.

J Steroid Biochem Mol Biol. 2014 Sep;143:424-33. doi: 10.1016/j.jsbmb.2014.06.007. Epub 2014 Jun 17.

PMID:
24950029
45.

Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study.

Zivadinov R, Chin J, Horakova D, Bergsland N, Weinstock-Guttman B, Tamaño-Blanco M, Badgett D, Hagemeier J, Tyblova M, Carl E, Krasensky J, Vaneckova M, Seidl Z, Dwyer MG, Havrdova E, Ramanathan M.

J Neuroimmunol. 2014 Aug 15;273(1-2):58-64. doi: 10.1016/j.jneuroim.2014.04.012. Epub 2014 Apr 30.

PMID:
24907902
46.

Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes.

Browne RW, Weinstock-Guttman B, Horakova D, Zivadinov R, Bodziak ML, Tamaño-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Havrdova E, Ramanathan M.

J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):859-64. doi: 10.1136/jnnp-2013-307106. Epub 2014 Jan 27.

PMID:
24470599
47.

Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study.

Dolezal O, Gabelic T, Horakova D, Bergsland N, Dwyer MG, Seidl Z, Krasensky J, Ramasamy DP, Vaneckova M, Havrdova E, Zivadinov R.

Clin Neurol Neurosurg. 2013 Dec;115 Suppl 1:S42-8. doi: 10.1016/j.clineuro.2013.09.020.

PMID:
24321154
48.

Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes.

Weinstock-Guttman B, Horakova D, Zivadinov R, Tamaño-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Havrdova E, Ramanathan M.

J Neuroimmunol. 2013 Oct 15;263(1-2):121-7. doi: 10.1016/j.jneuroim.2013.07.010. Epub 2013 Aug 2.

PMID:
23916695
49.

Thalamic atrophy is associated with development of clinically definite multiple sclerosis.

Zivadinov R, Havrdová E, Bergsland N, Tyblova M, Hagemeier J, Seidl Z, Dwyer MG, Vaneckova M, Krasensky J, Carl E, Kalincik T, Horáková D.

Radiology. 2013 Sep;268(3):831-41. doi: 10.1148/radiol.13122424. Epub 2013 Apr 23.

PMID:
23613615
50.

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.

Weinstock-Guttman B, Zivadinov R, Horakova D, Havrdova E, Qu J, Shyh G, Lakota E, O'Connor K, Badgett D, Tamaño-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z, Ramanathan M.

J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1186-91. doi: 10.1136/jnnp-2012-304740. Epub 2013 Apr 17.

PMID:
23595944

Supplemental Content

Loading ...
Support Center